Tvardi Therapeutics
TVRD
57 hedge funds and large institutions have $4.24M invested in Tvardi Therapeutics in 2026 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 24 reducing their positions, and 20 closing their positions.
5.08% less ownership
Funds ownership: 28.82% → 23.74% (-5.1%)
15% less funds holding
Funds holding: 67 → 57 (-10)
40% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 20
68% less capital inflows, than outflows
Capital inflows: $688K | Capital outflows: $2.18M
71% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$190K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$104K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$62.5K |
| 4 |
Savant Capital
Rockford,
Illinois
|
+$61K |
| 5 |
GSA Capital Partners
London,
United Kingdom
|
+$56.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$918K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$288K |
| 3 |
State Street
Boston,
Massachusetts
|
-$199K |
| 4 |
Great Lakes Advisors
Chicago,
Illinois
|
-$115K |
| 5 |
Vanguard Portfolio Management
Malvern,
Pennsylvania
|
-$108K |
TVRD Hedge Fund Activity: Q2 2026 in Review
57 of the 8,362 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2026, worth a combined $4.24M — down 51% from $8.6M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TVRD and 12 opened new positions — a net loss of 8 holders — while 24 trimmed existing stakes and 7 added.
The largest buyer was UBS Group, adding an estimated $190K. The largest seller was BlackRock, cutting an estimated $918K.
- 57 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2026, down from 67 in Q1 2026.
- Funds reported $4.24M of Tvardi Therapeutics stock for Q2 2026, down 51% quarter-over-quarter.
- 12 funds opened new Tvardi Therapeutics positions in Q2 2026 and 20 closed out, a net change of -8 holders.
- The largest Tvardi Therapeutics buyer in Q2 2026 was UBS Group, an estimated $190K added.
- The largest Tvardi Therapeutics seller in Q2 2026 was BlackRock, an estimated $918K sold.
Based on aggregated 13F filings for Q2 2026.